BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15716281)

  • 1. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
    Lim MJ; Spencer FA; Gore JM; Dabbous OH; Agnelli G; Kline-Rogers EM; Dibenedetto D; Eagle KA; Mehta RH;
    Eur Heart J; 2005 Jun; 26(11):1063-9. PubMed ID: 15716281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
    Tricoci P; Roe MT; Mulgund J; Newby LK; Smith SC; Pollack CV; Fintel DJ; Cannon CP; Bhatt DL; Gibler WB; Ohman EM; Peterson ED; Harrington RA
    Arch Intern Med; 2006 Apr; 166(7):806-11. PubMed ID: 16606819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S;
    Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
    Zeymer U; Gitt AK; Zahn R; Jünger C; Bauer T; Köth O; Heer T; Wienbergen H; Gottwik M; Senges J
    Acute Card Care; 2008; 10(1):43-8. PubMed ID: 17924233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice.
    Zeymer U; Gitt AK; Jünger C; Heer T; Wienbergen H; Koeth O; Bauer T; Mark B; Zahn R; Gottwik M; Senges J;
    Eur Heart J; 2006 Nov; 27(22):2661-6. PubMed ID: 17043060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).
    Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL;
    Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
    Rao RV; Goodman SG; Yan RT; Spencer FA; Fox KA; DeYoung JP; Rose B; Grondin FR; Gallo R; Gore JM; Yan AT;
    Am Heart J; 2009 Apr; 157(4):642-50.e1. PubMed ID: 19332190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
    Mehta RH; Roe MT; Mulgund J; Ohman EM; Cannon CP; Gibler WB; Pollack CV; Smith SC; Ferguson TB; Peterson ED
    J Am Coll Cardiol; 2006 Jul; 48(2):281-6. PubMed ID: 16843176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
    Roe MT; Armstrong PW; Fox KA; White HD; Prabhakaran D; Goodman SG; Cornel JH; Bhatt DL; Clemmensen P; Martinez F; Ardissino D; Nicolau JC; Boden WE; Gurbel PA; Ruzyllo W; Dalby AJ; McGuire DK; Leiva-Pons JL; Parkhomenko A; Gottlieb S; Topacio GO; Hamm C; Pavlides G; Goudev AR; Oto A; Tseng CD; Merkely B; Gasparovic V; Corbalan R; Cinteză M; McLendon RC; Winters KJ; Brown EB; Lokhnygina Y; Aylward PE; Huber K; Hochman JS; Ohman EM;
    N Engl J Med; 2012 Oct; 367(14):1297-309. PubMed ID: 22920930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
    Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl.
    Spencer FA; Goldberg RJ; Gore JM; Fox KA; Avezum A; Agnelli G; Kritharides L; Anderson FA; Goodman SG; FitzGerald G; Allegrone J; Brieger D;
    Am J Cardiol; 2007 Sep; 100(6):913-8. PubMed ID: 17826369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
    J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.